American Association for the Study of Liver Diseases, The Liver Meeting®

American Association for the Study of Liver Diseases, The Liver Meeting®
November 15-19, 2024
San Diego, California, USA

AASLD-2024.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (23)

    Kinetics of Hepatitis B Surface Antigen Loss Following 8 Years of Tenofovir-based Treatment in Hepatitis B e Antigen-negative and Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B

    • Author(s): Heo, J
    • vemlidy
    • Liver Diseases
    • Oral

    Associations Between Biomarkers and Magnetic Resonance Imaging-Derived ANALI Score in Patients with Primary Sclerosing Cholangitis: Analysis from the Phase 3 PRIMIS Study

    • Author(s): Trauner, M
    • cilofexor
    • Liver Diseases
    • Oral

    Similar Rates of Biochemical Response Are Observed Across Virologic Response Categories Over 96 Weeks of Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta

    • Author(s): Lampertico, P
    • hepcludex
    • Liver Diseases
    • Poster

    Long-term safety of seladelpar with up to 5 years of treatment in patients with primary biliary cholangitis

    • Author(s): Trivedi, P
    • livdelzi
    • Inflammation
    • Poster

    Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for 24 Months From the ASSURE Study

    • Author(s): Lawitz, E
    • livdelzi
    • Inflammation
    • Poster

    Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once-Daily for 6 Days in Participants with Moderate and Severe Hepatic Impairment and in Matched Control Participants with Normal Hepatic Function

    • Author(s): Kumar, P
    • hepcludex
    • Liver Diseases
    • Poster

    Hepatitis B surface antigen (HBsAg) response in patients with chronic hepatitis delta receiving bulevirtide with or without pegylated interferon alfa-2a in MYR204

    • Author(s): Liu, Y
    • hepcludex
    • Liver Diseases
    • Poster

    Assessing the Health-related Quality of Life, Impairment and Productivity among Individuals with PBC and Pruritus: Results from the ITCH-E Study

    • Author(s): Levy, C
    • livdelzi
    • Inflammation
    • Poster

    SELADELPAR AND REDUCTIONS IN LIPIDS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS WITH AND WITHOUT STATIN USE IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE STUDY

    • Author(s): Bowlus, C
    • livdelzi
    • Inflammation
    • Poster

    ATTENUATION, NEAR RESOLUTION, AND PREVENTION OF PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS TREATED WITH SELADELPAR: A SECONDARY ANALYSIS OF PATTERNS OF PRURITUS CHANGE IN THE RESPONSE TRIAL

    • Author(s): Kremer, A
    • livdelzi
    • Inflammation
    • Oral

    EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AND COMPENSATED CIRRHOSIS IN THE PHASE 3 PLACEBO-CONTROLLED RESPONSE TRIAL

    • Author(s): Villamil, A
    • livdelzi
    • Inflammation
    • Oral

    Results From a Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Novel Combination Therapies Containing VIR-2218, Selgantolimod, and Nivolumab for the Treatment of Chronic Hepatitis B

    • Author(s): Wong, G
    • selgantolimod
    • Liver Diseases
    • Poster

    Barodelta study: Real world data (RWD) of patient's characteristics, adherence, persistence, and empowerment in patients with chronic hepatitis Delta and treated by bulevirtide (BLV) 2 mg. Analysis from the French National Health Data System (SNDS).

    • Author(s): Asselah, T
    • hepcludex
    • Liver Diseases
    • Poster

    Pharmacokinetics, Pharmacodynamics, and Safety of Bulevirtide 2 mg Once-Daily for 6 Days in Participants Normal and Severely Impaired Renal Function 

    • Author(s): Wang, Y
    • hepcludex
    • Liver Diseases
    • Poster

    Biomarkers Associate with Fibrosis Progression in Patients with Primary Sclerosing Cholangitis: An Ad-hoc Analysis from the PRIMIS Study

    • Author(s): Trauner, M
    • cilofexor
    • Liver Diseases
    • Poster

    Efficacy and safety of BLV monotherapy for chronic hepatitis delta: post treatment results through 48 weeks after the end of treatment from an interim analysis of a randomized Phase 3 study MYR301

    • Author(s): Aleman, S
    • hepcludex
    • Liver Diseases
    • Poster

    The SVR10K study: A Real-World Data with Pangenotypic Direct-Acting Antivirals Across Multiple Diverse Regions

    • Author(s): Wong, G
    • epclusa
    • Liver Diseases
    • Poster

    Immunologic Biomarker Dynamics in Chronic Hepatitis B: Insights From a Phase 2a Open-Label Study on Combination Therapies With siRNA, Selgantolimod, and Nivolumab

    • Author(s): Pan, D
    • selgantolimod
    • Liver Diseases
    • Poster

    Immune-Related Adverse Events With Low-Dose Nivolumab in Patients With Chronic Hepatitis B: Experience From 3 Clinical Studies

    • Author(s): Gane, E
    • selgantolimod
    • Liver Diseases
    • Poster

    A Phase 1b, Open-Label Study to Evaluate the Safety and Efficacy of Novel Hepatitis B Virus Combination Therapies in Patients Living with Chronic Hepatitis B (CHB)

    • Author(s): Gane, E
    • selgantolimod
    • Liver Diseases
    • Poster

    Treatment persistence and discontinuation among chronic hepatitis B patients initiating antiviral treatment

    • Author(s): Makhija, D
    • vemlidy
    • Liver Diseases
    • Poster

    Characterization of Changes in Noninvasive Fibrosis Markers Over 8 years of Tenofovir-based Treatment in Chronic Hepatitis B Patients Enrolled in Two Phase 3 Trials

    • Author(s): Castera, L
    • livdelzi
    • Inflammation
    • Poster

    The REAL Study: Real-world Evaluation of ALP Normalization in PBC Patients Receiving Treatment

    • Author(s): Kowdley, K
    • livdelzi
    • Inflammation
    • Poster